Nuvectis Pharma (NVCT) Institutional Ownership $7.59 +0.07 (+0.93%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$7.82 +0.24 (+3.10%) As of 02/21/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Nuvectis Pharma (NASDAQ:NVCT)CurrentInstitutional OwnershipPercentage96.77%Number ofInstitutional Buyers(last 12 months)17TotalInstitutional Inflows(last 12 months)$2.96MNumber ofInstitutional Sellers(last 12 months)4TotalInstitutional Outflows(last 12 months)$378.54K Get NVCT Insider Trade Alerts Want to know when executives and insiders are buying or selling Nuvectis Pharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data NVCT Institutional Buying and Selling by Quarter Nuvectis Pharma Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/17/2025 Squarepoint Ops LLC19,071$103K0.0%N/A0.099% 2/17/2025 Two Sigma Investments LP18,570$100K0.0%-30.7%0.096% 2/17/2025 Millennium Management LLC29,698$161K0.0%-56.6%0.154% 2/17/2025 Cubist Systematic Strategies LLC6,294$34K0.0%N/A0.033% 2/14/2025 Northern Trust Corp25,725$139K0.0%+68.7%0.133% 2/13/2025 Marshall Wace LLP124,571$674K0.0%+191.0%0.645% 2/12/2025 Edmond DE Rothschild Holding S.A.15,170$82K0.0%-20.9%0.079% 2/12/2025 Baxter Bros Inc.15,000$81K0.0%+20.0%0.078% 2/5/2025 Oppenheimer & Co. Inc.25,000$135K0.0%N/A0.129% 1/30/2025 Nations Financial Group Inc. IA ADV13,500$73K0.0%+35.0%0.070% Get the Latest News and Ratings for NVCT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Nuvectis Pharma and its competitors with MarketBeat's FREE daily newsletter. 1/28/2025 Forbes J M & Co. LLP59,000$319K0.0%+21.9%0.305% 1/22/2025 Baldwin Wealth Partners LLC MA355,961$1.93M0.1%+104.4%1.842% 11/16/2024 Geode Capital Management LLC79,716$501K0.0%+49.8%0.413% 11/5/2024 GSA Capital Partners LLP50,129$315K0.0%+3.7%0.269% 11/5/2024 Nations Financial Group Inc. IA ADV10,000$63K0.0%N/A0.054% 10/25/2024 Iridian Asset Management LLC CT55,380$348K0.1%N/A0.297% 9/16/2024 Point72 Asia Singapore Pte. Ltd.9,203$58K0.0%N/A0.050% 8/15/2024 Point72 Asia Singapore Pte. Ltd.9,203$58K0.0%N/A0.050% 8/14/2024 Marshall Wace LLP33,868$214K0.0%-32.4%0.185% 8/9/2024 Renaissance Technologies LLC74,500$472K0.0%+20.7%0.406% 7/16/2024 Baxter Bros Inc.12,500$79K0.0%N/A0.068% 7/12/2024 Baldwin Brothers LLC MA168,630$1.07M0.1%+9.4%0.918% 5/10/2024 Vanguard Group Inc.298,800$2.45M0.0%+1.5%1.626% 4/18/2024 Blue Zone Wealth Advisors LLC14,350$118K0.0%N/A0.081% 2/12/2024 Edmond DE Rothschild Holding S.A.19,170$160K0.0%N/A0.111% 1/30/2024Strs Ohio6,200$51K0.0%+59.0%0.036% 1/8/2024 Baldwin Brothers LLC MA142,040$1.19M0.1%+22.0%0.820% 11/2/2023 Forbes J M & Co. LLP34,000$438K0.1%-49.3%0.197% 10/26/2023Strs Ohio3,900$50K0.0%+178.6%0.023% 10/10/2023 Baldwin Brothers LLC MA116,380$1.50M0.1%+29.2%0.675% 8/10/2023 Hollencrest Capital Management3,040$49K0.0%N/A0.019% 8/4/2023 American International Group Inc.3,298$53K0.0%N/A0.021% 8/3/2023 Forbes J M & Co. LLP67,000$1.07M0.1%N/A0.418% 8/2/2023 Bank of Montreal Can11,012$200K0.0%N/A0.069% 7/14/2023 Baldwin Brothers LLC MA90,061$1.44M0.1%-37.4%0.563% 5/11/2023 Edmond DE Rothschild Holding S.A.24,570$322K0.0%N/A0.167% 4/21/2023 Baldwin Brothers LLC MA143,800$1.89M0.2%+7.9%0.975% 11/4/2022Ronit Capital LLP562,547$3.99M5.4%+34.2%3.843% 10/14/2022 Baldwin Brothers LLC MA133,000$943K0.1%+9.9%0.908% 8/4/2022Ronit Capital LLP419,282$4.70M6.7%-23.8%3.297% Buy this AI Stock Before Elon’s Announcement (Ad)With Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dust. This isn't just a prediction; it's a calculated shift backed by political support, policy changes, and Musk's proven track record. I've identified a company that is quietly enabling xAI's rapid growth.Click here to watch my presentation and learn how to invest today.7/18/2022 Baldwin Brothers LLC MA121,000$1.36M0.2%N/A0.951% 5/11/2022Ronit Capital LLP550,000$4.08M5.1%N/A4.325% (Data available from 1/1/2016 forward) NVCT Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of NVCT shares? During the previous two years, 24 institutional investors and hedge funds held shares of Nuvectis Pharma. The most heavily invested institutionals were Vanguard Group Inc. ($2.45M), Baldwin Wealth Partners LLC MA ($1.93M), Baldwin Brothers LLC MA ($1.07M), Marshall Wace LLP ($674K), Geode Capital Management LLC ($501K), Renaissance Technologies LLC ($472K), and Iridian Asset Management LLC CT ($348K).Learn more on NVCT's institutional investors. What percentage of Nuvectis Pharma stock is owned by institutional investors? 96.77% of Nuvectis Pharma stock is owned by institutional investors. Learn more on NVCT's institutional investor holdings. Which institutional investors have been buying Nuvectis Pharma stock? Of the 22 institutional investors that purchased Nuvectis Pharma stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Baldwin Wealth Partners LLC MA ($181.83K), Marshall Wace LLP ($81.76K), Forbes J M & Co. LLP ($77.60K), Baldwin Brothers LLC MA ($76.98K), Iridian Asset Management LLC CT ($55.38K), Edmond DE Rothschild Holding S.A. ($43.74K), and Geode Capital Management LLC ($26.49K). How much institutional buying is happening at Nuvectis Pharma? Institutional investors have bought a total of 707,125 shares in the last 24 months. This purchase volume represents approximately $5.53M in transactions. Which Nuvectis Pharma major shareholders have been selling company stock? The following institutional investors have sold Nuvectis Pharma stock in the last 24 months: Baldwin Brothers LLC MA ($53.74K), Millennium Management LLC ($38.80K), Forbes J M & Co. LLP ($33K), Marshall Wace LLP ($16.20K), Two Sigma Investments LP ($8.22K), and Edmond DE Rothschild Holding S.A. ($4K). How much institutional selling is happening at Nuvectis Pharma? Institutional investors have sold a total of 153,955 shares in the last 24 months. This volume of shares sold represents approximately $1.66M in transactions. Related Companies TKNO Major Shareholders SNDL Major Shareholders TRDA Major Shareholders KMDA Major Shareholders MLYS Major Shareholders RNAC Major Shareholders ALT Major Shareholders MREO Major Shareholders PROK Major Shareholders ERAS Major Shareholders This page (NASDAQ:NVCT) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredShocking Elon Move: Bigger than DOGE?After saving free speech with his acquisition of Twitter… And after blowing everyone’s minds with his recen...Brownstone Research | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvectis Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvectis Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.